# US 2014/0194354 A1 · Methods for Treatment of Nephrotic Syndrome and Related Conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194354 A1
- Document ID: US20140194354A1
- Status: Published application
- Kind: A1
- Application number: 13/841,240
- Filed: 2013-03-15
- Published: 2014-07-10
- Earliest claimed: 2010-06-05
- Assignees: The UAB Research Foundation
- Inventors: Sumant S CHUGH
- Web page: https://patentgrep.com/patent/US20140194354A1

## CPC

- C07K 14/47: from mammals
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/38: Albumins
- A61K 38/42: Haemoglobins; Myoglobins
- A61P 3/06: Antihyperlipidemics
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 13/12: of the kidneys
- C07K 14/515: Angiogenesic factors; Angiogenin
- C07K 14/76: Albumins
- C07K 14/765: Serum albumin, e.g. HSA
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- A61K 9/1275: Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
- C07K 14/775: Apolipopeptides
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.

## Claims

### Claim 1

A method for the treatment or prevention of nephrotic syndrome in a subject, said method comprising administering to the subject a pharmaceutical composition comprising an Angptl4 polypeptide derivative having decreased LPL inhibitory activity, the Angptl4 polypeptide derivative comprising the following structure:
V—W—X—Y—Z
wherein
V is a sequence having at least 95% homology with SEQ ID NO: 23, wherein positions 39-55 are not DEMNVLAHGLLQLGQGL (positions 39-55 of SEQ ID NO: 1);
W is an oligopeptide of 0-5 residues;
X is a sequence having at least 95% homology with SEQ ID NO: 24;
Y is an oligopeptide of 0-38 residues; and
Z is a sequence having at least 95% homology with SEQ ID NO: 25.

### Claim 2 (depends on 1)

The method of claim 1, wherein positions 39-40 of V is not DE, position 46 of V is not H, position 50 of V is not Q, and position 53 of V is not Q.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sequence at positions 39-40 of SEQ ID NO: 23 is not DE.

### Claim 4 (depends on 1)

The method of claim 1, wherein position 39 of SEQ ID NO: 23 is a positively charged residue or a neutral residue.

### Claim 5 (depends on 1)

The method of claim 1, wherein position 40 of SEQ ID NO: 23 is a negatively charged residue or a neutral residue.

### Claim 6 (depends on 1)

The method of claim 1, wherein position 40 of SEQ ID NO: 23 is selected from the residues shown in Table 1.

### Claim 7 (depends on 1)

The method of claim 1, wherein position 39 of SEQ ID NO: 23 is K or A.

### Claim 8 (depends on 1)

The method of claim 1, wherein position 40 of SEQ ID NO: 23 is K, A or E.

### Claim 9 (depends on 1)

The method of claim 1, wherein position 39 of SEQ ID NO: 23 is K or A, and wherein position 40 of SEQ ID NO: 23 is K, A, or E.

### Claim 10 (depends on 1)

The method of claim 1, wherein the sequence at positions 39 and 40 of SEQ ID NO: 23 is selected from the group consisting of DK, KE, DA, and AE.

### Claim 11 (depends on 1)

The method of claim 1, wherein the sequence at positions 63-66 of SEQ ID NO: 24 is not RRKR, and wherein the Angptl4 polypeptide has increased resistance to cleavage.

### Claim 12 (depends on 11)

The method of claim 11, wherein one or more of positions 63-66 of SEQ ID NO: 24 are independently selected from the group consisting of D, R, K, G, A, V, and S.

### Claim 13 (depends on 11)

The method of claim 11, wherein all of positions 63-66 of SEQ ID NO: 24 are independently selected from the group consisting of D, R, K, G, A, V, and S.

### Claim 14 (depends on 11)

The method of claim 11, wherein one or more of positions 63-66 of SEQ ID NO: 24 are independently selected from the group consisting of G, A, S, and V.

### Claim 15 (depends on 11)

The method of claim 11, wherein all of positions 63-66 of SEQ ID NO: 24 are independently selected from the group consisting of G, A, S, and V.

### Claim 16 (depends on 11)

The method of claim 11, wherein the sequence at positions 63-66 of SEQ ID NO: 24 is selected from Table 2.

### Claim 17 (depends on 11)

The method of claim 11, wherein of the sequence at positions 63-66 of SEQ ID NO: 24 is selected from the group consisting of GAAG (SEQ ID NO: 29), GSGS (SEQ ID NO: 80), GVVA (SEQ ID NO: 49), SGGG (SEQ ID NO: 87), and VAVA (SEQ ID NO: 90).

### Claim 18 (depends on 11)

The method of claim 11, wherein of the sequence at positions 63-66 of SEQ ID NO: 24 is selected from GSGS (SEQ ID NO: 80), SGGG (SEQ ID NO: 87), and GVVA (SEQ ID NO: 49).

### Claim 19 (depends on 1)

The method of claim 1, wherein the sequence at positions 39-40 of SEQ ID NO: 23 is DK and the sequence at positions 63-66 of SEQ ID NO: 24 is GSGS (SEQ ID NO: 80).

### Claim 20 (depends on 1)

The method of claim 1 wherein the sequence at positions 39-40 of SEQ ID NO: 23 is KE and the sequence at positions 63-66 of SEQ ID NO: 24 is SGGG (SEQ ID NO: 87).

### Claim 21 (depends on 1)

The method of claim 1 wherein the sequence at positions 39-40 of SEQ ID NO: 23 is DA and the sequence at positions 63-66 of SEQ ID NO: 24 is GVVA (SEQ ID NO: 49).

### Claim 22 (depends on 1)

The method of claim 1, wherein said structure is:
A-B—C
wherein
A has at least 95% homology with SEQ ID NO: 26, wherein the sequence at positions 39-55 is not DEMNVLAHGLLQLGQGL (positions 39-55 of SEQ ID NO: 1);
B is an oligopeptide of 0-38 residues; and
C has at least 95% homology with SEQ ID NO: 27.

### Claim 23 (depends on 1)

The method of claim 1, wherein the Angptl4 polypeptide derivative has at least 95% sequence homology with SEQ ID NO: 9.

### Claim 24 (depends on 1)

The method of claim 1, wherein the Angptl4 polypeptide derivative has at least 95% homology with SEQ ID NO: 10.

### Claim 25 (depends on 1)

The method of claim 1, wherein the Angptl4 polypeptide derivative is sialylated.

### Claim 26 (depends on 1)

The method of claim 1, comprising administering the pharmaceutical composition to the subject at a dosage of about 0.05-150,000 μg/kg.

### Claim 27 (depends on 1)

The method of claim 1, comprising administering the pharmaceutical composition to the subject at a dosage of about 50-150 μg/kg.

### Claim 28 (depends on 1)

The method of claim 1, wherein the Angptl4 polypeptide derivative is administered in a therapeutically effective amount.

### Claim 29 (depends on 1)

The method of claim 1, comprising administering the pharmaceutical composition to the subject about once per 14 days.

### Claim 30 (depends on 1)

The method of claim 1, comprising administering the pharmaceutical composition to the subject about twice per month.

### Claim 31 (depends on 1)

The method of claim 1, comprising administering the pharmaceutical composition to the subject from about once per month to about twice per month.

### Claim 32 (depends on 1)

The method of claim 1, comprising a step to deliver the Angptl4 polypeptide derivative to the subject's blood.

### Claim 33 (depends on 1)

The method of claim 1, comprising administering the pharmaceutical composition to the subject intravenously.

### Claim 34 (depends on 1)

The method of claim 1, wherein the nephrotic syndrome is characterized as minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy/membranous glomerulonephritis, membranoproliferative glomerulonephritis or a diabetic condition.

### Claim 35 (depends on 1)

The method of claim 1, wherein the administering reduces edema, reduces proteinuria, increases plasma albumin levels, reduces hypercholesterolemia, reduces hypertriglyceridemia or a combination of the foregoing.

### Claim 36 (depends on 1)

The method of claim 1 wherein the nephrotic condition is minimal change disease.

### Claim 37 (depends on 1)

The method of claim 1, wherein the nephrotic condition is diabetic ephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease.
